Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10,630 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study.
Aoki D, Tabata T, Yanagida S, Nakamura T, Kondo E, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Kato A, Suri A, Okamoto A, Sugiyama T. Aoki D, et al. Among authors: nakamura h, nakamura t. J Gynecol Oncol. 2024 Sep;35(5):e114. doi: 10.3802/jgo.2024.35.e114. J Gynecol Oncol. 2024. PMID: 39251349 Free PMC article. Clinical Trial.
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer.
Okamoto A, Kondo E, Nakamura T, Yanagida S, Hamanishi J, Harano K, Hasegawa K, Hirasawa T, Hori K, Komiyama S, Matsuura M, Nakai H, Nakamura H, Sakata J, Tabata T, Takehara K, Takekuma M, Yokoyama Y, Kase Y, Sumino S, Soeda J, Suri A, Aoki D, Sugiyama T. Okamoto A, et al. Among authors: nakamura h, nakamura t. J Gynecol Oncol. 2021 Mar;32(2):e16. doi: 10.3802/jgo.2021.32.e16. Epub 2020 Dec 10. J Gynecol Oncol. 2021. PMID: 33327047 Free PMC article. Clinical Trial.
Efficacy and safety of olaparib, olaparib plus bevacizumab and niraparib maintenance treatment in Japanese patients with platinum-sensitive advanced ovarian cancer.
Nakamura K, Matsuoka H, Yorimitsu M, Ogawa M, Kanemori M, Sueoka K, Kozai A, Nakamura H, Haruma T, Shiroyama Y, Hayata Y, Sugii H, Ueda A, Kurihara S, Urayama S, Shimizu M, Masuyama H. Nakamura K, et al. Among authors: nakamura h. Jpn J Clin Oncol. 2024 Jan 7;54(1):31-37. doi: 10.1093/jjco/hyad125. Jpn J Clin Oncol. 2024. PMID: 37721176 Free PMC article.
Relationship Between Hematological Toxicities During Maintenance Treatment and During Chemotherapy Before Maintenance Treatment in Patients With Platinum-sensitive Relapsed Ovarian Cancer.
Matsuoka H, Nakamura K, Yorimitsu M, Ogawa M, Kanemori M, Sueoka K, Kozai A, Nakamura H, Haruma T, Shiroyama Y, Hayata Y, Sugii H, Ueda A, Kurihara S, Urayama S, Shimizu M, Masuyama H. Matsuoka H, et al. Among authors: nakamura h, nakamura k. Anticancer Res. 2023 Aug;43(8):3653-3658. doi: 10.21873/anticanres.16546. Anticancer Res. 2023. PMID: 37500145
A survey of carboplatin desensitization therapy in Japan: A multicenter retrospective study.
Komatsu H, Matsumoto K, Morita M, Nagasawa T, Nishio H, Suzuki J, Nishio S, Kobara H, Yunokawa M, Ariyoshi K, Hirayama T, Tokunaga H, Ukita M, Yoriki K, Mori-Uchino M, Furusawa A, Togami S, Nakamura H, Ishikawa M, Satoh T. Komatsu H, et al. Among authors: nakamura h. Cancer Med. 2024 Mar;13(5):e6968. doi: 10.1002/cam4.6968. Cancer Med. 2024. PMID: 38491829 Free PMC article.
10,630 results
You have reached the last available page of results. Please see the User Guide for more information.